Stockscreener 앱 받기
2.05
0.99%
0.02
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
US Stocks Recap: Is Milestone Pharmaceuticals Inc vulnerable to short sellers2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: How does Milestone Pharmaceuticals Inc compare to its peersWeekly Trend Summary & Long-Term Growth Plans - baoquankhu1.vn
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Institutional Moves & Technical Pattern Recognition Alerts - Bộ Nội Vụ
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing - TipRanks
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView — Track All Markets
Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Trend Report: Will Milestone Pharmaceuticals Inc stock gain from government policies2025 Volume Leaders & Safe Capital Growth Tips - Bộ Nội Vụ
How Milestone Pharmaceuticals Inc. stock benefits from global expansion2025 Growth vs Value & Real-Time Market Sentiment Alerts - Улправда
How supply chain issues affect Milestone Pharmaceuticals Inc. stockJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Will Milestone Pharmaceuticals Inc. stock gain from government policies2025 Sector Review & Risk Managed Investment Strategies - Улправда
Can Milestone Pharmaceuticals Inc. stock continue upward trendJuly 2025 Sentiment & Capital Efficient Trading Techniques - Улправда
Is Milestone Pharmaceuticals Inc. stock a buy in volatile markets2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Milestone announces acceptance of MAA by EMA for etripamil nasal spray - Yahoo Finance
MIST: HC Wainwright & Co. Reiterates Buy Rating with $8 Price Ta - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Milestone Pharmaceuticals Says EMA Accepts Marketing Application for Etripamil Nasal Spray - marketscreener.com
Milestone’s PSVT nasal spray MAA accepted by EMA - TipRanks
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - The Manila Times
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Travel Stocks: How Milestone Pharmaceuticals Inc stock trades before earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Bộ Nội Vụ
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval - StocksToTrade
Milestone Pharmaceuticals (MIST) price target increased by 76.00% to 6.73 - MSN
Wyckoff Accumulation Phase Possible in Aveer Foods LimitedVWAP Trading Strategies & Double Or Triple Profits - earlytimes.in
Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen - MarketBeat
Will Milestone Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Earnings & Fast Moving Stock Trade Plans - Улправда
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Milestone Pharmaceuticals Inc. stock deliver strong Q4 earningsChart Signals & Long-Term Growth Portfolio Plans - Улправда
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
Can Milestone Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Trading Recap & Real-Time Stock Entry Alerts - Улправда
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Business Wire
What is HC Wainwright's Estimate for MIST FY2026 Earnings? - MarketBeat
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) - FinancialContent
Wells Fargo maintains Milestone Pharmaceuticals (MIST) overweight recommendation - MSN
Wells Fargo Maintains Milestone Pharmaceuticals (MIST) Overweight Recommendation - Nasdaq
Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Wells Fargo Raises Price Target for Milestone Pharmaceuticals (M - GuruFocus
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval - Yahoo Finance
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) - Seeking Alpha
Milestone Embarks On ‘Show-Me’ Story With Cardamyst Launch - Citeline News & Insights
HC Wainwright & Co. Maintains Milestone Pharmaceuticals (MIST) Buy Recommendation - Nasdaq
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com Canada
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals (MIST) Stock Jumps 35% on Groundbreaking FDA Approval - parameter.io
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):